The University of Texas MD Anderson Cancer Center has honored two outstanding nurses, Kimberly Vanderhorst and Terri Lynn Dunn, with the 2025 Brown Foundation Award for Excellence in Oncology Nursing. The award recognizes exceptional patient care and a commitment to excellence in clinical practice.
The Mays Cancer Center stands among the nation's leading institutions recognized for excellence in cancer care and research. It is one of only four NCI-designated Cancer Centers in Texas, offering specialized programs and delivering comprehensive, multidisciplinary care supported by clinical research.
The ESMO Guidance on the Use of Large Language Models in Clinical Practice (ELCAP) provides a structured set of recommendations for safely adopting AI language models in oncology. The guidance emphasizes the importance of human oversight, transparent tools, and continuously monitored systems to ensure trust in AI-driven cancer care.
Patients receiving mRNA-based COVID vaccines showed improved survival rates and responses to immunotherapy, especially in 'cold' tumors with low PD-L1 expression. The study suggests that these vaccines can reprogram immune responses against cancer, potentially improving outcomes for patients with treatment-resistant disease.
The ESMO Congress 2025 will cover key topics including precision oncology, antibody-drug conjugates in breast cancer, dose optimisation strategies, new treatment modalities for melanoma, and immunotherapy-based approaches across various cancer settings. Promising Phase-3 studies on ADCs in bladder and lung cancer are also expected.
A novel gene therapy targets and kills cancer cells infected with the Kaposi's sarcoma-associated herpesvirus (KSHV), while leaving healthy cells unharmed. The treatment uses a harmless virus to deliver a genetic 'Trojan horse' into infected cells, converting an anti-herpesvirus drug into a cancer-killing agent.
The WIN Symposium, featuring oncology experts, aims to accelerate the translation of research into clinical practice through keynote lectures and networking opportunities. The event is part of the Advancing Precision Medicine (APM) Annual Conference 2025.
Researchers identified specific ways to address religion and spirituality during radiation therapy, highlighting their importance in patient coping mechanisms. The study found that nearly all patients considered spiritual history questions helpful, especially those related to coping with stress.
Cancer rehabilitation programs in Australia have more than doubled since 2015, yet many survivors face barriers to accessing exercise-based care. According to a national survey, nearly half of respondents cite lack of funding as a challenge to program sustainability.
Researchers at Fox Chase Cancer Center found adaptive radiation therapy can reduce radiation to healthy tissue by 21% while delivering higher doses to tumors. The study offers new hope for patients with previously untreatable cancers.
A retrospective study found that radiation therapy controlled ventricular tachycardia with fewer complications than standard catheter ablation. Radiation therapy was similarly effective in controlling arrhythmia and showed lower serious side effects, especially in the early time window.
A large phase III trial found that stereotactic body radiation therapy (SBRT) preserves quality of life, with fewer declines in bowel and urinary functioning. However, SBRT does not outperform standard radiation therapy for disease-free survival, with higher rates of biochemical failure and rising PSA after treatment.
Dr. Amar Kishan has been recognized for his groundbreaking research on radiation treatments for genitourinary system cancers. He is the recipient of the 2025 Steven A. Leibel Memorial Award, presented by ASTRO and ABR Foundation.
The NRG-GU005 clinical study shows that SBRT significantly improves bowel health-related quality of life in patients with localized immediate risk prostate cancer. However, no significant improvement was seen for urinary HRQOL, and SBRT was not superior to IMRT in terms of distant-free survival.
A new randomized study validates a predictive gene expression test that identifies patients with recurrent prostate cancer who will benefit from adding hormone therapy to radiation. The test, PAM50, groups tumors into molecular subtypes and predicts treatment outcomes.
The University of Cincinnati Cancer Center researchers are presenting several studies on radiation oncology, including the evaluation of efficacy and safety of proton re-irradiation in head and neck cancers, significant variation in oropharyngeal cancer treatment approaches, and severe toxicity rare following liver cancer ablative radi...
Researchers from UCLA presented findings on targeted radioactive therapy, new SBRT approaches and advances in MRI- and 5DCT-guided imaging. The LUNAR clinical trial looked at adding a targeted therapy before ablative radiotherapy for men with recurrent prostate cancer.
The NRG Oncology PREDICT-RT study has completed patient accrual, evaluating intensified and de-intensified concurrent radiation regimens for high-risk prostate cancer patients. The study aims to improve quality of life and outcomes by tailoring treatments based on genomic risk scores.
The Alliance for Clinical Trials in Oncology will host a public webinar showcasing key findings from the 2025 ASCO Annual Meeting. Researchers will discuss latest information on colorectal, squamous cell, and renal cell cancers.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.
Experts weighed in on the current state of artificial intelligence (AI) in cancer care, noting both its potential for improving efficiency and its challenges. Many expressed excitement over AI's possibilities for helping support an overburdened oncology workforce and accelerating the pursuit of new cures.
A study published in Oncoscience found that over 60% of oncology healthcare professionals in Morocco showed signs of severe burnout, with emotional exhaustion being the key factor. The study highlights the need for urgent institutional changes to support healthcare workers and improve work environments.
The Molecular Analysis for Precision Oncology Congress 2025 (MAP) brings together leading experts to explore the latest cancer research advances. Key topics include AI-integrated diagnostics and therapy, as well as immunotherapy and emerging developments in aging and cellular senescence.
The Ellen Siow Professorship aims to advance education and research in neuro-oncology, specifically glioblastoma. This will drive the development of innovative programmes and interventions, fostering progress that benefits people in Singapore and beyond.
Dr. Catheryn Yashar, a renowned radiation oncologist, has been appointed president-elect of the American Society for Radiation Oncology (ASTRO). She will champion innovative radiation therapies and advance health policy reform to improve cancer care outcomes.
Julie Bauman, MD, MPH, is appointed Deputy Chair of NRG's NCORP Research Base, while Ryan Burri, MD, becomes the VA-MTF Subcommittee Vice Chair. These appointments aim to enhance cancer research and treatment through multi-center clinical studies.
The inaugural ESMO Targeted Anticancer Therapies (TAT) Asia Congress 2025 will convene a diverse group of stakeholders to foster collaboration and accelerate the development of innovative cancer therapies. The congress aims to become a catalyst for global collaboration and innovation in oncology.
NRG Oncology has appointed Tambre Leighn as Chair of the Patient Advocate Committee and Chris Holsinger as Surgical Vice Chair of the Head and Neck Cancer Committee. These new leaders will focus on advancing patient advocate engagement and expanding NRG's head and neck cancer portfolio.
The American Society for Radiation Oncology (ASTRO) has updated its guideline on radiation therapy for high-grade diffuse gliomas, the most common primary brain tumor in adults. The new guideline provides evidence-based recommendations for multidisciplinary treatment and addresses optimal radiation dosing, fractionation, and techniques.
A new precision oncology paper presents a case of a 62-year-old man with metastatic colorectal cancer who underwent multiple lines of therapy. The WIN International Molecular Tumor Board proposed personalized treatment plans based on the tumor's unique genetic mutations, highlighting the growing role of precision oncology in guiding th...
Researchers discovered a new tumor-suppressive response targeting RNA Polymerase 1, inhibiting cancer cell growth and enhancing responsiveness to immunotherapies. The Pol 1 inhibitor BOB-42 reduced tumor growth by up to 77% in melanoma and colorectal cancers.
ASTRO welcomes Karen Davis as its first Vice President of Business Development and Marketing, leading the organization's business growth strategy. Davis will focus on public- and private-sector partnerships to advance ASTRO's mission and broaden its impact on cancer care.
Experts from the National Comprehensive Cancer Network (NCCN) and African Cancer Coalition gathered in Nairobi, Kenya to update NCCN Clinical Practice Guidelines in Oncology for Sub-Saharan Africa. The meeting aimed to improve cancer care in the region by sharing evidence-based recommendations.
The Dresden research team developed an autonomous AI agent for precision medicine that can process multimodal data and have reasoning capabilities. The AI agent reached correct clinical conclusions in 91% of cases and accurately cited relevant oncology guidelines in over 75% of its responses.
A recent study published in JAMA Oncology suggests that modern phase 3 oncology trials often prioritize overall survival over quality of life, which may not accurately reflect patient needs. Future trial designs should focus on improving overall survival and quality-of-life outcomes to better represent patient experiences.
The ATOMIC trial demonstrates a statistically significant improvement in disease-free survival with the addition of atezolizumab to standard adjuvant FOLFOX chemotherapy. Patients treated with atezolizumab had a 50% lower risk of disease recurrence or death compared to those receiving chemotherapy alone.
A phase II clinical trial shows that combining immune checkpoint inhibition with avelumab and cetuximab significantly improves progression-free survival compared to avelumab alone for patients with advanced cutaneous squamous cell carcinoma. The combination also leads to a confirmed objective response rate of 27.6%.
A new algorithm standardizes care for children with sickle cell disease who present to the ED with a fever, reducing hospitalizations by 10% without increasing readmissions. The algorithm uses predefined risk factors to determine treatment, making it safer and more efficient.
Researchers from Mayo Clinic Comprehensive Cancer Center will present practice-changing studies on chemotherapy approaches, AI applications in oncology, and new therapies for breast and melanoma. The event will feature 59 abstracts highlighting advancements in cancer care.
Researchers examined baseline characteristics of adolescent and young adult (AYA) cancer survivors seen in oncology primary care clinic, finding high rates of comorbidities and cardiovascular disease. They also studied the overexpression of IRAK4 protein in acute myeloid leukemia (AML) cells, with potential implications for treatment.
Christopher Flowers is being recognized for his commitment to mentoring young oncology professionals. He has advanced the development of multiple new treatments and helped characterize disparities in outcomes among patients with lymphoma.
Tracy Crane has been appointed as the new Chair of the NRG CPC Committee, focusing on improving adherence to healthy lifestyle behaviors, while Mylin Torres joins as Vice-Chair, leading research on breast cancer and radiation-induced side effects. Both experts bring extensive experience in clinical trials and mentorship.
The study found key differences in tumor biology between non-Hispanic Black and non-Hispanic white veterans, but similar survival outcomes when both groups had equal access to care. The research highlights the importance of broadening access to genomic tools and prioritizing equity in cancer treatment.
The American Society for Radiation Oncology (ASTRO) will host its 67th Annual Meeting in San Francisco from September 27 to October 1, 2025. The meeting will feature over 2,500 research presentations and posters on advances in radiation oncology and non-cancer indications.
City of Hope experts will present new cancer treatment approaches, targeted therapies and lifestyle changes aimed at reducing cancer risk and improving survival. Highlights include discussions on biomarkers in kidney cancer, symptom science and palliative care.
The NCCN Policy Summit brought together experts to discuss ways to strengthen collaborative cancer care, from early detection to survivorship. Key findings include the need for better communication and coordination between primary care and oncology providers.
Kristin Higgins has been appointed Chair of the NRG Lung Cancer Committee, succeeding Dr. Jeff Bradley, while Karthik Sundaram joins as Chair of the NRG Imaging Committee, succeeding Dr. Daniel Pryma. These appointments aim to advance research and clinical trials in these areas.
A new review advocates for building confidence in AI applications by implementing robust data governance frameworks, enhancing transparency, and involving stakeholders. The authors emphasize the importance of addressing ethical implications and ensuring equitable access to AI-driven innovations in clinical oncology.
At the 2025 Oncology Nursing Society Congress, Dana-Farber nurse scientists and clinicians presented key studies on hypersensitivity reaction simulation, bispecific antibody therapy, primary nursing, and non-pharmacologic interventions for anxiety and pain reduction. These research initiatives aim to enhance patient care, education, an...
NGR Oncology has created a new Sarcoma Subcommittee to improve outcomes for adults with cancer, focusing on building a robust program, collaborating with the Children's Oncology Group, and promoting sarcoma research. The subcommittee is led by Chair Dian Wang, MD, PhD, and Vice-Chairs William Tseng, MD, and Brian A Van Tine, MD, PhD.
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
The new Keck Medicine of USC – Newport Beach Radiation Oncology and Imaging Center offers biology-guided radiation therapy, using up-to-the-minute signals to track and treat cancer cells in real time. The center is equipped with state-of-the-art technology and will be the first in Orange County to provide this treatment option.
Jeffrey E. Lee, M.D. has been appointed Chief Medical Executive at MD Anderson, succeeding Dr. Peter WT Pisters. With over 34 years of tenure, Lee will lead the institution's efforts in research, patient care, prevention, and education. He brings a strong track record of leadership and clinical expertise to the role.
The collaboration aims to enhance clinical trial efficiency, reducing data entry time by up to 37 seconds per CRF. This enables researchers to focus more on patient care, improving the overall experience.
The NRG Oncology GOG-0263 phase III clinical trial found that adding cisplatin-based chemotherapy to adjuvant radiotherapy following radical hysterectomy did not improve outcomes and led to increased toxicity. Radiotherapy alone remains the standard of care for early-stage, intermediate-risk cervical cancer.
The F. W. Bert and Mae Dean Wheeler Nurse Leadership Academy at MD Anderson aims to cultivate oncology nurse leaders through coaching, mentoring, and continuous learning opportunities. The academy will focus on empowering nurses to reach their personal and professional goals, driving industry change and improving healthcare systems.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for anal cancer, providing guidance on treatment options and techniques. The guideline recommends a combination of radiation therapy and drug therapy as the standard of care, with intensity-modulated radiation therapy (IM...
Kimberly Stegmaier appointed as Chair of Pediatric Oncology at Dana-Farber Cancer Institute and Associate Chief of Division of Hematology/Oncology at Boston Children's Hospital. She will focus on acute leukemias and pediatric solid tumors, pioneering genomic approaches to identify new therapies for childhood cancer.
Dr. Gordon was named a Fellow of the American Society of Clinical Oncology (FASCO) in recognition of his extraordinary dedication to improving cancer research and patient outcomes. He has led HonorHealth Research Institute's clinical trials programs and contributed significantly to developing new cancer treatments.
The ACC Advancing the Cardiovascular Care of the Oncology Patient conference will provide clinicians with tools to improve cardiovascular care of cancer patients. Key sessions will include discussions on pulmonary tumor thrombotic microangiopathy, AI and technology in cardio-oncology.